LuMIERE: A Phase 1/2, Multicenter, Open-label,Non-randomized Study to Investigate Safety and Tolerability,Pharmacokinetics, Dosimetry, and Preliminary Activity of177Lu-FAP-2286 in Patients with an Advanced Solid Tumor
Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer
Sponsor: Clovis Oncology, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT7518
U.S. Govt. ID: NCT04939610
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP). Cancers include: bladder cancer, brain and spinal tumors, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, kidney cancer, liver cancer, lung cancer, skin cancers, pancreatic cancer, prostate cancer, sarcomas, stomach cancer, testicular cancer, and thyroid cancer.
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator